Recent Reports


2011-11-14: Biotechnology and Pharmaceuticals Report
5 leading Analysts; and top management from 4 Sector Firms examine this industry.
Order this Report
More Information

2011-10-31: Health Care IT Report
4 leading Analysts; and top management from 5 Sector Firms examine this industry.
Order this Report
More Information

2011-10-17: Medical Research, Diagnostic Substances & Life Science Tools Report
4 leading Analysts; and top management from 3 Sector Firms examine this industry.
Order this Report
More Information

2011-10-03: Medical Real Estate Report
3 leading Analysts; and top management from 3 Sector Firms examine industry.
Order this Report
More Information

2011-07-11: Medical Devices Report
5 leading Analysts; and top management from 12 Sector Firms examine this industry.
Order this Report
More Information

2011-06-27: Health Care IT Report
6 leading Analysts; and top management from 9 Sector Firms examine this industry.
Order this Report
More Information

2011-06-13: Medical Research, Diagnostic Substances & Life Science Tools Report
5 leading Analysts; and top management from 3 Sector Firm examine this industry.
Order this Report
More Information

2011-04-04: Biotechnology and Pharmaceuticals Report
3 leading Analysts; and top management from 5 Sector Firms examine this industry.
Order this Report
More Information

2011-01-24: Medical Devices Report
3 leading Analysts; and top management from 9 Sector Firms examine this industry.
Order this Report
More Information

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
WAYNE SMITH - COMMUNITY HEALTH SYSTEMS INC (CYH)


Full article published: 09/20/2000


For Subscribers

Get this article online now!

Order just this article
TWST: Could you start by giving us a brief overview and profile of Community Health Systems?
Mr. Smith: Community Health Systems was founded in 1985, went public in 1991 at 8/share and then was acquired in an LBO by Forstmann Little & Co., Ted Forstmann's company, for 52/share in the summer of 1996. I was recruited by Forstmann Little and arrived here in January 1997. We currently have 51 facilities in 20 states. In 84% of our markets, we're the sole provider in those communities. Last year, we had revenues in excess of 1 billion and EBITDA over 200 million. From 1997 to 1999, we had about 21% revenue growth, compounded annually, and a 29% EBITDA growth, and we improved our margins about 2.4% during this same period. We just released our second-quarter earnings, and net revenues for the quarter ending June 30, 2000 totaled 317.1 million, a 21.1% increase over the prior year. Adjusted EBITDA for the second quarter of 2000 was 59.8 million, a 19.6% increase over the prior year. Net income was 0.2 million compared with 1.8 million loss for the second quarter last year. Same hospital net revenues increased by 10.5% with admissions up 7.8% versus second quarter of last year. We also improved our same hospital adjusted EBITDA margin to 19.9% from 19.1% in the second quarter of last year.

TWST: The hospital market has been in trouble lately. How have you guys done so well?
Mr. Smith: We're in the non-urban markets, which we believe to be the most attractive sector in healthcare. We think the non-urban markets obviously offer great opportunities for us because there's little or no competition; the markets represent about 25% of the US population and have underserved healthcare needs. As I said earlier, in about 84% of our markets, we're the sole provider. We have very limited managed care. The demographics are really good in the smaller markets in that there's a growing population of Medicare in those markets. The economy is generally good in the communities where we operate because of diverse industry. So we've focused on non-urban markets that meet our criteria, and we have implemented a standardized and centralized operating model, which works well for us.

 

Tickers included in this excerpt: CYH

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.